Correlation Between Bristol Myers and Eyenovia

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Eyenovia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Eyenovia into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bristol Myers Squibb and Eyenovia, you can compare the effects of market volatilities on Bristol Myers and Eyenovia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Eyenovia. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Eyenovia.

Diversification Opportunities for Bristol Myers and Eyenovia

BristolEyenoviaDiversified AwayBristolEyenoviaDiversified Away100%
-0.09
  Correlation Coefficient

Good diversification

The 3 months correlation between Bristol and Eyenovia is -0.09. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Eyenovia in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eyenovia and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Eyenovia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eyenovia has no effect on the direction of Bristol Myers i.e., Bristol Myers and Eyenovia go up and down completely randomly.

Pair Corralation between Bristol Myers and Eyenovia

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.19 times more return on investment than Eyenovia. However, Bristol Myers Squibb is 5.13 times less risky than Eyenovia. It trades about 0.01 of its potential returns per unit of risk. Eyenovia is currently generating about -0.07 per unit of risk. If you would invest  6,047  in Bristol Myers Squibb on December 2, 2024 and sell it today you would lose (85.00) from holding Bristol Myers Squibb or give up 1.41% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Bristol Myers Squibb  vs.  Eyenovia

 Performance 
JavaScript chart by amCharts 3.21.15Dec2025Feb -80-60-40-2002040
JavaScript chart by amCharts 3.21.15BMY EYEN
       Timeline  
Bristol Myers Squibb 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong primary indicators, Bristol Myers is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
JavaScript chart by amCharts 3.21.15JanFebFebMar5455565758596061
Eyenovia 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Eyenovia has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
JavaScript chart by amCharts 3.21.15JanFebFebMar24681012141618

Bristol Myers and Eyenovia Volatility Contrast

   Predicted Return Density   
JavaScript chart by amCharts 3.21.15-4.77-3.57-2.38-1.180.01.182.43.634.856.07 0.050.100.15
JavaScript chart by amCharts 3.21.15BMY EYEN
       Returns  

Pair Trading with Bristol Myers and Eyenovia

The main advantage of trading using opposite Bristol Myers and Eyenovia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Eyenovia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will offset losses from the drop in Eyenovia's long position.
The idea behind Bristol Myers Squibb and Eyenovia pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Complementary Tools

Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Transaction History
View history of all your transactions and understand their impact on performance
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA